Comparison of a new HFA 134a-formulated budesonide pMDI with a standard CFC-formulated budesonide pMDI in children with persistent asthma

G. Lefrancois, E. Rigamonti, J. Hofman, I. Kottakis (Parma, Italy; Bialystok, Poland)

Source: Annual Congress 2005 - Paediatric asthma drug therapy
Session: Paediatric asthma drug therapy
Session type: Thematic Poster Session
Number: 1052
Disease area: Airway diseases, Paediatric lung diseases

Congress or journal article abstract

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
G. Lefrancois, E. Rigamonti, J. Hofman, I. Kottakis (Parma, Italy; Bialystok, Poland). Comparison of a new HFA 134a-formulated budesonide pMDI with a standard CFC-formulated budesonide pMDI in children with persistent asthma. Eur Respir J 2005; 26: Suppl. 49, 1052

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you: